Photo by mojaghrout from unsplash
increased from 14 (IQR[9-17) to 18 (IQR[11-26). Six patients were re-treated with repeat HGCryo, and two patients had salvage brachytherapy. No serious adverse events were encountered. CONCLUSIONS: HGCryo for csCaP… Click to show full abstract
increased from 14 (IQR[9-17) to 18 (IQR[11-26). Six patients were re-treated with repeat HGCryo, and two patients had salvage brachytherapy. No serious adverse events were encountered. CONCLUSIONS: HGCryo for csCaP is well-tolerated and appears potentially curative at 18 months follow-up, when evaluated by MRIGB. Freedom from csCaP, found in nearly 80% of patients, appears durable from 6 to 18 months of follow-up. The possibility of contralateral csCaP, found in 8.7% of men at 18 months, suggests that both targeted and systematic biopsies are advisable at long-term follow-up.
Journal Title: Journal of Urology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!